Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT

Add to watchlist

$15.576

+1.27

+8.92%

Market closed

Open in 3 days

+34.65%

month

+34.65%

quarter

+373.51%

year

Market Cap	1.80B
Enterprise value	934.67M

P/E	-2.1
EV/Sales	253.57
EV/EBITDA	-3.16
Price/Sales	213.17
Price/Book	3.74
PEG ratio	0.05
EPS	-2.92

Revenue	106.39M
EBITDA	-189.87M
Income	-217.42M
Revenue Q/Q	1682.41%
Revenue Y/Y	1545.18%

Profit margin	-8449.76%
Oper. margin	-8183.04%
Gross margin	79.54%
EBIT margin	-8183.04%
EBITDA margin	-178.46%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Profit margin
Jun 2023	5.19M	-70.99M	-1367.84%
Sep 2023	38.10M	-44.76M	-117.47%
Dec 2023	13.52M	-66.28M	-490.05%
Mar 2024	49.56M	-35.38M	-71.38%

Arcutis Biotherapeutics Financials Estimate

Q Y

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Analyst Estimates
Dec 2023	13.52M	-66.28M	-490.05%
Mar 2024	49.56M	-35.38M	-71.38%
Oct 2025	71M	-27.76M	-39.1%
Dec 2025	71M	-27.76M	-39.1%

Analysts Price target
Financials & Ratios estimates

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Debt to assets
Jun 2023	320689000	240.18M	74.9%
Sep 2023	292959000	246.24M	84.05%
Dec 2023	341365000	252.69M	74.03%
Mar 2024	478541000	253.59M	52.99%

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Cash Flow
Jun 2023	-66.48M	89.11M	1.06M
Sep 2023	-43.98M	45.54M	867K
Dec 2023	-56.24M	-62.18M	99.28M
Mar 2024	-31.60M	-28.69M	161.76M

Arcutis Biotherapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Arcutis Biotherapeutics
Employees

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Employee count
Aug 2023	268
Sep 2023	268
Oct 2023	268
Nov 2023	268
Dec 2023	268
Jan 2024	268
Feb 2024	268
Mar 2024	296
Apr 2024	296
May 2024	296
Jun 2024	296
Jul 2024	296

Arcutis Biotherapeutics
Hedge Funds Holdings Q1 2023

63.89% -36.11%

of ARQT is owned by hedge funds

82 -57

hedge funds hold ARQT stock

35.16M -30.91M

shares is hold by hedge funds

ARQT hedge funds holdings changes

Arcutis Biotherapeutics
Insider Trading

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	1325
Feb 2024	0	2465
Mar 2024	21052	26913
May 2024	0	115402
Jun 2024	0	10000
Jul 2024	0	10000
Aug 2024	0	44641
Sep 2024	0	21626
Oct 2024	0	13725
Nov 2024	4788	89289
Dec 2024	0	25000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	20 Dec 2024	WATANABE TODD FRANKLIN director, officer..	Common Stock	15,000	$15.17	$227,565
Sale	2 Dec 2024	WELGUS HOWARD G. director director	Common Stock	10,000	$12.51	$125,130
Purchase	30 Nov 2024	EDWARDS LARRY TODD officer: See Remarks officer: See Remarks	Common Stock	1,093	$7.11	$7,767
Purchase	30 Nov 2024	MATSUDA MASARU officer: See Rema..	Common Stock	1,657	$7.11	$11,775
Purchase	30 Nov 2024	WATANABE TODD FRANKLIN director, officer..	Common Stock	2,038	$7.11	$14,482
Option	22 Nov 2024	BURNETT PATRICK officer: See Rema..	Stock Option (right to buy)	16,023	$3.64	$58,324
Option	22 Nov 2024	BURNETT PATRICK officer: See Rema..	Common Stock	16,023	N/A	N/A
Sale	22 Nov 2024	BURNETT PATRICK officer: See Rema..	Common Stock	16,023	$10.14	$162,521
Sale	19 Nov 2024	MATSUDA MASARU officer: See Rema..	Common Stock	1,775	$9.69	$17,191
Option	15 Nov 2024	BURNETT PATRICK officer: See Rema..	Stock Option (right to buy)	100	$3.64	$364

ARQT insider trading transactions

Arcutis Biotherapeutics
Patents

Status	Patent	Filling date	Issue date
Application	Application TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS Filling date: 24 Mar 2022 Issue date: 7 Jul 2022	24 Mar 2022	7 Jul 2022
Application	Application TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES Filling date: 3 Dec 2021 Issue date: 9 Jun 2022	3 Dec 2021	9 Jun 2022
Application	Application COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERY Filling date: 16 Nov 2021 Issue date: 19 May 2022	16 Nov 2021	19 May 2022
Application	Application COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERY Filling date: 16 Nov 2021 Issue date: 19 May 2022	16 Nov 2021	19 May 2022
Application	Application METHODS FOR TREATING VITILIGO LESIONS HAVING IMPROVED EFFICACY Filling date: 28 Oct 2021 Issue date: 5 May 2022	28 Oct 2021	5 May 2022
Application	Application LAURETH-4 CONTAINING TOPICAL FORMULATIONS Filling date: 27 Jul 2021 Issue date: 3 Feb 2022	27 Jul 2021	3 Feb 2022
Application	Application TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF LIFE Filling date: 13 Aug 2021 Issue date: 16 Dec 2021	13 Aug 2021	16 Dec 2021
Application	Application METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS Filling date: 21 May 2021 Issue date: 9 Sep 2021	21 May 2021	9 Sep 2021
Application	Application ROFLUMILAST FORMULATIONS WITH AN IMPROVED PHARMACOKINETIC PROFILE Filling date: 5 Feb 2021 Issue date: 3 Jun 2021	5 Feb 2021	3 Jun 2021

ARQT patents

Arcutis Biotherapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 14 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 27 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 3 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 8 Aug 2023	Q2 2023 Earnings Call Transcript

ARQT earnings call transcripts

Arcutis Biotherapeutics
Executives

Insider	Age	Compensation
Mr. Todd Franklin Watanabe (1968) Pres, Chief Executive Officer & Director	57	$734,630
Dr. Patrick E. Burnett M.D., Ph.D. (1972) Senior Vice President & Chief Medical Officer	53	$619,790
Mr. Kenneth A. Lock (1974) Chief Commercial Officer	51	$514,280
Dr. Bhaskar Chaudhuri Ph.D. (1955) Co-Founder & Independent Director	70	$50,420

Arcutis Biotherapeutics
Latest News

Thursday, 26 December 2024
11:32	What Awaits These 4 Biotech Stocks That More Than Doubled in 2024	zacks.com
Friday, 6 December 2024
16:00	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Wednesday, 27 November 2024
11:01	Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?	zacks.com
11:00	Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?	zacks.com
Wednesday, 20 November 2024
10:31	Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors	zacks.com
10:31	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average	zacks.com
Tuesday, 19 November 2024
10:56	Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now	zacks.com
10:35	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average	zacks.com
Friday, 15 November 2024
08:30	Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?	seekingalpha.com
Monday, 11 November 2024
11:00	Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?	zacks.com
Thursday, 7 November 2024
02:24	Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript	seekingalpha.com
Wednesday, 6 November 2024
18:21	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
16:00	Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Monday, 4 November 2024
16:00	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Friday, 25 October 2024
11:06	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release	zacks.com
Wednesday, 23 October 2024
16:00	Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference	globenewswire.com
Friday, 18 October 2024
08:20	Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older	globenewswire.com
Friday, 4 October 2024
16:00	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Wednesday, 25 September 2024
01:00	New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types	globenewswire.com
Tuesday, 24 September 2024
08:00	FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over	globenewswire.com
Thursday, 5 September 2024
16:00	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 22 August 2024
17:13	Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely	seekingalpha.com
08:00	Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference	globenewswire.com
Thursday, 15 August 2024
00:43	Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript	seekingalpha.com
Wednesday, 14 August 2024
21:00	CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
18:12	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates	zacks.com
16:00	Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Wednesday, 7 August 2024
11:06	Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know	zacks.com
Friday, 2 August 2024
16:00	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Monday, 29 July 2024
07:35	Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.	globenewswire.com

Ideas & Opinions

Seeking Alpha 25 Jun 2025

Arcutis Biotherapeutics: Another Approval Under Their Belt
Seeking Alpha 13 Jun 2025

Arcutis: Out Of The Woods, Ready For Commercialization
Seeking Alpha 5 Jun 2025

Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside
Seeking Alpha 19 Apr 2025

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets
Seeking Alpha 31 Jan 2024

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Seeking Alpha 13 Nov 2023

Arcutis Biotherapeutics: Almost There, But Needs Some Fine-Tuning
Seeking Alpha 20 Aug 2023

Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal
Seeking Alpha 2 Aug 2023

Rare Buy Picks In July 2023 - From 29 Discerning Analysts
Seeking Alpha 28 Jul 2023

Arcutis: Zoryve - A Challenging Launch With Progress
Seeking Alpha 24 Apr 2023

Arcutis Biotherapeutics: PDUFA Date Before End Of 2023 Makes This Worth A Look

Frequently Asked Questions (FAQ)

What's the price of Arcutis Biotherapeutics stock today?

One share of Arcutis Biotherapeutics stock can currently be purchased for approximately $15.58.
When is Arcutis Biotherapeutics's next earnings date?

Unfortunately, Arcutis Biotherapeutics's (ARQT) next earnings date is currently unknown.
Does Arcutis Biotherapeutics pay dividends?

No, Arcutis Biotherapeutics does not pay dividends.
How much money does Arcutis Biotherapeutics make?

Arcutis Biotherapeutics has a market capitalization of 1.80B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1517.09% to 59.61M US dollars.
What is Arcutis Biotherapeutics's stock symbol?

Arcutis Biotherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ARQT".
What is Arcutis Biotherapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Arcutis Biotherapeutics?

Shares of Arcutis Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Arcutis Biotherapeutics's key executives?
Arcutis Biotherapeutics's management team includes the following people:
- Mr. Todd Franklin Watanabe Pres, Chief Executive Officer & Director(age: 57, pay: $734,630)
- Dr. Patrick E. Burnett M.D., Ph.D. Senior Vice President & Chief Medical Officer(age: 53, pay: $619,790)
- Mr. Kenneth A. Lock Chief Commercial Officer(age: 51, pay: $514,280)
- Dr. Bhaskar Chaudhuri Ph.D. Co-Founder & Independent Director(age: 70, pay: $50,420)
Is Arcutis Biotherapeutics founder-led company?

Yes, Arcutis Biotherapeutics is a company led by its founder Dr. Bhaskar Chaudhuri Ph.D..
How many employees does Arcutis Biotherapeutics have?

As Jul 2024, Arcutis Biotherapeutics employs 296 workers.
When Arcutis Biotherapeutics went public?

Arcutis Biotherapeutics, Inc. is publicly traded company for more then 5 years since IPO on 31 Jan 2020.
What is Arcutis Biotherapeutics's official website?

The official website for Arcutis Biotherapeutics is arcutis.com.
Where are Arcutis Biotherapeutics's headquarters?

Arcutis Biotherapeutics is headquartered at 3027 Townsgate Road, Westlake Village, CA.
How can i contact Arcutis Biotherapeutics?

Arcutis Biotherapeutics's mailing address is 3027 Townsgate Road, Westlake Village, CA and company can be reached via phone at 805 418 5006.

Arcutis Biotherapeutics, Inc.

arcutis.com

Exchange:

NASDAQ

Full time employees:

296

Industry:

Biotechnology

Sector:

Healthcare

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

805 418 5006

3027 Townsgate Road
Westlake Village, CA 91361

CIK: 0001787306
ISIN: US03969K1088
CUSIP: 03969K108